REVIEW article
Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1594234
This article is part of the Research TopicAdvances in Redox System Pharmacology for Treating Resistant DiseasesView all articles
Research on the function of GPX4 in tumor-targeted treatment based on its molecular structure and features
Provisionally accepted
- Shenzhen Children's Hospital, Shenzhen, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
..GPX4 is the only antioxidant enzyme in mammals that can convert cholesterol and phospholipid hydroperoxide into phosphatidylol and cholesterol.Its peculiar molecular structure allows it to perform a variety of biological functions, including oxidative stress, ferroptosis regulation, brain development stimulation, and immune responses.In recent years, several studies have demonstrated that increased GPX4 expression is linked to tumor cell proliferation, growth, migration, and differentiation.Overexpression of GPX4 has been linked to chemoresistance and a poor prognosis in cancers including nasopharyngeal carcinoma, breast cancer, and lung cancer. GPX4 inhibitors have been demonstrated to be effective in the treatment of numerous drug-resistant malignancies. Some tumors, such as glioblastoma, do not react well to single-agent GPX4 inhibitors. Therefore, future research should focus on identifying cancers that are more responsive to GPX4 inhibitors and enhancing the efficacy of these inhibitors.This research investigates the regulatory mechanisms and properties of GPX4 in various tumor cell types, as well as its molecular structure and biological roles, hoping to propose more effective tumor-targeted therapy alternatives.
Keywords: GPx4, ferroptosis, lung cancer, esophageal cancer, gastric cancer
Received: 15 Mar 2025; Accepted: 25 Aug 2025.
Copyright: © 2025 Geng, Ma, Wu, Yao, Wang, Gan, Li and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Fang Chen, Shenzhen Children's Hospital, Shenzhen, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.